News | August 08, 2024
JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
Expect the international business including CDMO business to pick-up in the second half of the financial year
Expect the international business including CDMO business to pick-up in the second half of the financial year
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA before special items falls 1.3 percent to € 4.41 billion
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Subscribe To Our Newsletter & Stay Updated
